Breast cancer metastasis-suppressor 1-like protein (BRMS1L)

Breast cancer metastasis-suppressor 1-like protein (BRMS1L) is a transcriptional repressor that is part of the mSin3a family of histone deacetylase (HDAC) complexes[1][3][4]. BRMS1L shows high sequence similarity to BRMS1, a proven metastasis-suppressor, and Sds3 proteins. The protein is downstream of the p53 pathway and is upregulated by p53 family members (p53, p63, p73), and functions to inhibit cancer cell invasion and migration—key steps in metastasis[2]. Its tumor-suppressive effects appear primarily through transcriptional repression mediated by HDAC1, and epigenetic silencing of pro-metastatic genes (such as FZD10, affecting the Wnt pathway)[5][2]. Loss or suppression of BRMS1L promotes epithelial–mesenchymal transition (EMT), invasion, and metastatic dissemination in cancer cells[1][2]. BRMS1L expression is reduced in several cancers, particularly breast, ovarian, and brain cancer, and lower levels are associated with poorer prognosis[2][5]. Subcellular (nuclear) presence of BRMS1L further correlates with reduced metastatic potential and improved outcomes[2]. Although no direct drug interactions are reported, targeting pathways that suppress BRMS1L expression is considered a potential therapeutic strategy for preventing cancer metastasis[1][2]. No significant safety concerns specific to BRMS1L targeting are reported in the literature, nor are any interacting drugs or direct inhibitors yet described.

Other names

Breast cancer metastasis-suppressor 1-like proteinBRMS1LMGC11296FLJ39177p40BRMS1-homolog protein p40BRMS1-like protein p40BRMS1